A Frustrating Quest: Why Biogen Could Be Our Best Hope For Alzheimer's Right Now

Published: Sep 28, 2017

A Biogen Inc. drug may be the next best hope in the long and frustrating search for a better Alzheimer’s disease treatment, following Tuesday’s news that another company’s experimental pill for the devastating condition didn’t work in a clinical trial.

The failure of New York startup Axovant Sciences’ drug, called intepirdine, was the latest in a long line of poor results for Alzheimer’s medicines.

Compounding the disappointment, the next chance for a breakthrough won’t come until 2019.

Back to news